Results 91 to 100 of about 1,327 (186)

Pharmaceutical composition comprising rimegepant [PDF]

The present invention relates to pharmaceutical composition comprising rimegepant or a pharmaceutically acceptable salts thereof and process for preparation which is simple, economic, cost-effective, and industrially amenable to scale up.
, Ravi Kumar Nithiyanandam
core   +1 more source

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +1 more source

Use of mediation modeling to examine the relationships among treatment with rimegepant, headache pain severity, and functional disability in patients with migraine

Cephalalgia Reports
Background Rimegepant improves both headache pain and physical function in clinical studies for the acute treatment of migraine. It is not clear whether rimegepant has direct effects on physical function or if improvements in function are an indirect ...
Lucy Abraham, Andrew G. Bushmakin, Dawn C. Buse, Joseph C. Cappelleri, David C. Semel, Elizabeth K. Seng   +5 more
doaj   +1 more source

Loss of Melanoregulin (MREG) Enhances Cathepsin-D Secretion by the Retinal Pigment Epithelium [PDF]

, 2013
Cathepsin-D (Cat-D) is a major proteolytic enzyme in phagocytic cells. In the retinal pigment epithelium (RPE), it is responsible for the daily degradation of photoreceptor outer segments (POSs) to maintain retinal homeostasis.
Boesze-Battaglia, Kathleen, Bragin, Alvina, Frost, Laura S., Lopes, Vanda S., Mitchell, Claire H., Stefano, Frank P., Williams, David S.   +6 more
core   +1 more source

New therapeutic options in migraine treatment [PDF]

Introduction and purpose Migraine is a common disease mostly affecting women. It has a huge influence on patients’ life strongly decreasing its quality by cause of repetitive headache episodes and often comes with unpleasant and burdensome symptoms like ...
Greguła, Anna, Kłos, Aleksandra, Lambach, Maciej, Mazur, Bartosz, Mazurek, Aleksnadra, Mika, Dawid, Pawlicki, Mateusz, Stachyrak, Karol, Turek, Kamila, Wilanowska, Wiktoria   +9 more
core   +1 more source

Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics

Journal of Pain Research
Terence Fullerton,1 Glenn Pixton2 1Internal Medicine and Infectious Disease, Pfizer Research and Development, Pfizer Inc., Groton, CT, USA; 2Statistics, Pfizer Inc., Groton, CT, USACorrespondence: Terence Fullerton, Internal Medicine and Infectious ...
Fullerton T, Pixton G
doaj  

Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study) [PDF]

Background: Focusing on calcitonin gene-related peptide (CGRP) as a specific target has changed and improved migraine management. After the positive results of monoclonal antibodies directed to the CGRP pathway (anti-CGRP mAbs), randomized controlled ...
Altamura, Claudia, Battistini, Stefania, Corrado, Michele, De Cesaris, Francesco, De Santis, Federico, Doretti, Alberto, Ferrandi, Delfina, Fofi, Luisa, Grazzi, Licia, Guerzoni, Simona, Iannone, Luigi Francesco, Italian Headache Registry (RICe) Study Group, Lo Castro, Flavia, Marcosano, Marilena, Montisano, Danilo Antonio, Munafò, Antonio, Ornello, Raffaele, Pistoia, Francesca, Rufa, Alessandra, Sacco, Simona, Sebastianelli, Gabriele, Vaghi, Gloria, Vernieri, Fabrizio   +22 more
core   +2 more sources

Determining the Advantageous Acute Migraine Treatment: Rimegepant and Lasmiditan Review of Literature [PDF]

, 2020
This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and Lasmiditan target the trigeminovascular system and respectively, are characterized in the gepant and ditan classes of pharmaceuticals.
Johnson, Tiffany A
core   +1 more source

CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine [PDF]

The study of migraine is based on the complexity of the pathology, both at the pathophysiological and epidemiological levels. Although it affects more than a billion people worldwide, it is often underestimated and underreported by patients.
Alessandro Santarsiere, Alessia Catalano, Antonio Vassallo, Carmela Saturnino, Carmen Scieuzo, Fabiano Svolacchia, Federica Giuzio, Francesca Finelli, Giuseppe Andrea Ferraro, Maria Stefania Sinicropi, Michele De Lisa, Rosanna Salvia, Sabino Genovese   +12 more
core   +1 more source

Medication-Overuse Headache: Update on Management [PDF]

Long-term frequent use of acute pain medication for the treatment of headaches has paradoxically been shown to increase the frequency of headaches. So-called medication-overuse headache (MOH) is particularly problematic in patients with migraine who ...
Koonalintip, Prut, Phillips, Katherine, Wakerley, Benjamin R.   +2 more
core   +1 more source